Results from this phase III trial of atezolizumab plus bevacizumab versus sunitinib for patients with untreated renal cell carcinoma (IMmotion 151) were published in The Lancet last month. The study involved 915 patients, of which 40% were positive for PD-L1 biomarkers. In the PD-L1 positive group of patients, the combination of atezolizumab plus bevacizumab was associated with longer median progression-free survival of 11.2 months versus 7.7 months for sunitinib.
The atezolizumab plus bevacizumab combination also seemed more tolerable, with fewer grade 3/4 adverse events and treatment discontinuations.
However, because overall survival data are not yet available, longer-term follow-up is needed to determine whether a survival difference exists between the two treatment groups.